acupuntura.com
LibraryAtlas
ExercisesNews
LibraryAtlas
ExercisesNews
acupuntura.com

Evidence-based medical acupuncture, physician-led at CEIMEC.

NAVIGATION

HomeArticlesConditionsAtlasMusclesExercises

CONTENT

NewsLibraryGuidesMultimodal

PATIENTS

SymptomsPain MapConditionsFAQFirst Session

INSTITUTIONAL

AboutTeamCEIMECWhy Trust Us

LEGAL

Editorial PolicyPrivacyTerms of UseLegal Notice

RESOURCE

Free Resource

No ads · No paywalls

01 · IDIOMA · LANGUAGE

Disponível em outras línguas

Disponible en otros idiomas

Available in other languages

Dr. Marcus Yu Bin Pai·Physician Acupuncturist

DISCLAIMER Information on acupuntura.com is educational and does not replace consultation with a qualified physician. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have.

acupuntura.com · 2025–2026Last reviewed: 2026-05-04
Back to News
MediaFull Analysis
April 13, 2026
6 min reading time

Memorial Sloan Kettering and JNCI: Two American Studies Validate Electroacupuncture for 'Brain Fog' in Breast Cancer Survivors

Phase 2 RCT with 260 women (MSK/SABCS 2025) and pilot RCT published in JNCI (April 2026) converge: electroacupuncture improves objective cognition and reduces psychological distress in breast cancer survivors — simultaneous coverage by ASCO Post and MSK signals a turning point in integrative oncology

Source: Memorial Sloan Kettering Cancer Center(in English)
Memorial Sloan Kettering and JNCI: Two American Studies Validate Electroacupuncture for 'Brain Fog' in Breast Cancer Survivors

Approximately 40% of breast cancer survivors develop treatment-related cognitive impairment — popularly called "brain fog" or chemo brain —, a condition that can persist years after the end of chemotherapy and the use of hormonal therapy. Difficulties with memory, attention, and processing speed compromise the quality of life, return to work, and emotional well-being of these patients. In less than five months, two randomized studies conducted by reference institutions in the United States published convergent evidence that electroacupuncture may offer a concrete therapeutic path for this problem — until now of difficult pharmacologic management.

The results of the Memorial Sloan Kettering study discussed below were presented at congress (SABCS, December 2025) and await peer-reviewed publication; this synthesis is preliminary in nature. The complementary UC Irvine study has already been published in the Journal of the National Cancer Institute (April 2026), but with a small pilot sample. The conclusions presented here should be interpreted in this context.

The first study, presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2025 by Dr. Jun Mao (Chief of the Integrative Medicine Service at Memorial Sloan Kettering Cancer Center), randomized 260 breast cancer survivors — stages 1 to 3, more than 50% with prior chemotherapy and about 67% on hormonal therapy at the time of recruitment — into three arms: real acupuncture (n=129), standard care (n=61), and sham acupuncture (n=70). The protocol included weekly sessions for 10 weeks, with cognitive assessments at baseline, at the end of treatment, and at 26 weeks. The study was funded by the National Cancer Institute and the NCI Cancer Center Support Grant, conferring independent rigor.

KEY DATA FROM THE TWO CLINICAL TRIALS

260
PARTICIPANTS (MSK STUDY)
Phase 2 RCT, 3 arms — SABCS Dec. 2025
35
PARTICIPANTS (UC IRVINE STUDY)
Double-blind pilot RCT — JNCI Apr. 2026
42.9%
OBJECTIVE COGNITIVE RESPONSE
Specific group vs. 12.5% control (UC Irvine)
50%
RESPONSE FOR PSYCHOLOGICAL DISTRESS
vs. 37.5% in the control group (UC Irvine)
P=0.033
INCREASE IN GRAY MATTER
Neuroimaging — specific acupoint group
10 weeks
TREATMENT PROTOCOL
Weekly sessions — both studies

The MSK study: distinguishing real effect from placebo effect

One of the most relevant findings of Dr. Mao’s study is the dissociation between subjective perception and objective cognitive performance. Both the real acupuncture group and the sham acupuncture group reported "clinically significant improvements" in the perception of memory, attention, and daily functioning — an expected result given the placebo effect inherent to any active care intervention. However, only the real acupuncture group demonstrated consistent improvement on standardized cognitive tests administered by a blinded team, evaluated at week 10 and at week 26. This separation between perceived effect and objective effect is methodologically robust and suggests, in preliminary analysis, that medical acupuncture may produce measurable cognitive changes beyond patient expectation.

WHAT IS CANCER-RELATED COGNITIVE IMPAIRMENT (CRCI)?

CRCI — also called cancer-related cognitive impairment or informally "brain fog" — refers to cognitive difficulties that arise during or after cancer treatment. It mainly affects working memory, processing speed, sustained attention, and executive function. It is estimated that 40% of breast cancer survivors report persistent symptoms, which can last years after the end of treatment.

Proposed mechanisms include chemotherapy-induced neuroinflammation, mitochondrial dysfunction, alterations in resting-state brain network connectivity, and direct neurotoxic effects of chemotherapeutic agents. Prolonged hormonal therapy — frequent in hormone-receptor-positive breast cancer — is an additional cognitive risk factor. To date, there is no pharmacotherapy approved specifically for CRCI, which makes non-pharmacologic interventions such as electroacupuncture especially relevant.

The UC Irvine study in JNCI: neuroimaging evidence

The second study, published in the Journal of the National Cancer Institute on April 13, 2026 by Dr. Alexandre Chan (UC Irvine), adopted a different and complementary methodologic approach. The pilot RCT with 35 breast cancer survivors compared electroacupuncture targeted at specific neuropsychiatric acupoints (n=21) versus control acupoints (n=14), in 10 weekly sessions. The double-blind design — previously considered unfeasible in acupuncture studies — was achieved with the use of control acupoints unrelated to the neuropsychiatric system.

The results showed that 42.9% of participants in the specific acupoints group presented measurable objective cognitive improvement at the end of treatment, compared with 12.5% in the control group. Attention improvement was significant both at the end of treatment (Δ = 0.562) and at the four-week follow-up (Δ = 0.708), suggesting durability of the benefit. Psychological distress also improved significantly: 50% of participants in the specific group responded to treatment for the distress outcome versus 37.5% of the control. All adverse events reported were grade 2 or lower.

The differential of this study was the incorporation of structural and functional neuroimaging. Participants who received electroacupuncture at specific neuropsychiatric acupoints presented greater gray matter volume (P=0.033), and this increase correlated with attention improvement (r=0.69; P=0.020). Default Mode Network connectivity decreased (r=-0.93; P<0.01) — a pattern associated with better attentional focus — while Dorsal Attention Network connectivity increased (r=0.86; P<0.001), indicating favorable functional reorganization of brain networks (high correlation values in a small sample should be interpreted with caution).

INSIGHT

I receive in the office breast cancer survivors who completed treatment one, two, three years ago and continue to report difficulty concentrating, forgetfulness, and a sensation of "foggy head" that affects professional life and social relationships. Until recently, I had little to offer beyond general guidance on sleep hygiene and exercise. These two studies change that conversation. The UC Irvine neuroimaging data is especially important for us: it suggests that electroacupuncture not only improves the subjective report — it is associated with measurable alterations in brain networks. For the medical acupuncturist who needs to justify the indication to the responsible oncologist, this structural and functional evidence is exactly what was missing. And the fact that it is the MSK — possibly the largest cancer center in the world — presenting and disseminating these results changes the clinical-political weight of the indication.
— Dr. Marcus Yu Bin Pai · CRM-SP 158074 · RQE 65523 / 65524 / 655241

LIMITATIONS AND POINTS OF ATTENTION

  • The UC Irvine study is a pilot RCT with only 35 participants — the results are promising, but require confirmation in larger-scale trials with adequate statistical power
  • The MSK study has not yet been published in a peer-reviewed scientific journal (presented at congress in December 2025) — awaits complete publication with detailed subgroup analysis
  • Most participants were Caucasian and recruited at high-level academic centers — generalization to diverse populations requires additional studies
  • Specific acupoint protocols for neuropsychiatric cognitive impairment are not yet standardized for broad clinical use — replication of findings depends on detailed description of the protocols
  • The durability of cognitive benefit beyond 26 weeks (MSK study) and 4 weeks of follow-up (UC Irvine) was not evaluated

IMPLICATIONS FOR INTEGRATIVE ONCOLOGY AND MEDICAL PRACTICE

  • Electroacupuncture emerges as a low-risk therapeutic candidate for cancer-related cognitive impairment, a condition without currently approved pharmacologic option
  • The approval and active dissemination by MSK and ASCO Post indicate that international reference oncology centers are incorporating medical acupuncture into the supportive-care portfolio
  • The oncologist may consider referring breast cancer survivor patients with persistent cognitive complaint for evaluation by a medical acupuncturist, as part of coordinated integrative care
  • Protocols should include objective cognitive assessment (neuropsychological tests) at the beginning and end of the treatment cycle, not only subjective measures
  • The 10-week therapeutic window with response evaluation appears to be the most studied model and may serve as a reference for initial protocols
FREQUENTLY ASKED QUESTIONS · 03

Frequently Asked Questions

The term 'brain fog' (or chemo brain) refers to cancer-related cognitive impairment — difficulties with memory, attention, thinking speed, and executive function that arise during or after cancer treatment. It is estimated that 40% of breast cancer survivors present these symptoms, which can persist years after the end of chemotherapy. The mechanism involves neuroinflammation, oxidative stress, and treatment-induced alterations in brain networks.

In the two studies described in this article, conducted in populations of breast cancer survivors (after completion of main treatment), electroacupuncture was well tolerated. The UC Irvine study recorded only adverse events grade 2 or lower. The decision to start acupuncture during or after cancer treatment should always be made together with the responsible oncologist, who will evaluate specific contraindications such as thrombocytopenia, anticoagulation, and location of treatment sites.

The mechanisms are still being investigated, but the UC Irvine study provides important clues: electroacupuncture at specific neuropsychiatric acupoints increased gray matter volume, reduced Default Mode Network connectivity (associated with rumination and distraction), and increased Dorsal Attention Network connectivity (associated with focus and attentional control). Reductions in neuroinflammation biomarkers were also described in exploratory analyses. Together, these findings suggest that electroacupuncture actively modulates the neural systems affected by cancer treatment.

Fonte Original

Memorial Sloan Kettering Cancer Center(em inglês)
Content prepared by
CEIMEC — Centro de Estudo Integrado de Medicina Chinesa

Founded in 1989 by physicians trained at the University of São Paulo (USP) and specialized in China, CEIMEC is a Brazilian national reference in the teaching and practice of medical acupuncture. With more than 3,000 physicians trained over 35 years, it collaborates with HC-FMUSP and is recognized by the Brazilian Medical College of Acupuncture (CMBA/AMB).

Published on 2026-04-13
All News